Advertisement
Screener

RECURSION PHARMACEUTICALS, INC. (RXRX) Executive Pay versus Performance: Pay versus Performance

RECURSION PHARMACEUTICALS, INC. Pay versus Performance

The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.

  • 2025-12-31: PEO 1.Christopher Gibson; PEO total compensation $9.61M; PEO compensation actually paid $3.48M; Other NEO average total compensation $3.34M.
  • 2024-12-31: PEO total compensation $8.50M; PEO compensation actually paid $1.91M; Other NEO average total compensation $6.05M.
  • 2023-12-31: PEO total compensation $8.61M; PEO compensation actually paid $10.68M; Other NEO average total compensation $4.12M.
  • 2022-12-31: PEO total compensation $6.32M; PEO compensation actually paid -$5.83M; Other NEO average total compensation $2.05M.
Fiscal year endPEOPEO total compensationPEO compensation actually paidOther NEO average total compensationOther NEO average compensation actually paidTotal shareholder returnPeer group total shareholder returnNet incomeCompany-selected measureProxy filed
2025-12-311.Christopher Gibson$9.61M$3.48M$3.34M-$518.66K$13.07$122.97-$644.76M2026-04-30
2024-12-31$8.50M$1.91M$6.05M$4.95M$21.60$92.16-$463.66M2026-04-30
2023-12-31$8.61M$10.68M$4.12M$4.97M$31.50$92.69-$328.07M2026-04-30
2022-12-31$6.32M-$5.83M$2.05M-$4.63M$24.63$88.62-$239.48M2026-04-30
2021-12-31$673.59K$21.79M$647.82K$13.68M$54.73$98.60-$186.48M2026-04-30
2024-12-311.Christopher Gibson$8.50M$1.91M$6.05M$4.95M$21.60$92.16-$463.66M2025-04-28
2023-12-31$8.61M$10.68M$4.12M$4.97M$31.50$92.69-$328.07M2025-04-28
2022-12-31$6.32M-$5.83M$2.05M-$4.63M$24.63$88.62-$239.48M2025-04-28
2021-12-31$673.59K$21.79M$647.82K$13.68M$54.73$98.60-$186.48M2025-04-28
2023-12-311.Christopher Gibson$8.61M$10.68M$4.12M$4.97M$31.50$92.69-$328.07M2024-04-23
2022-12-31$6.32M-$5.83M$2.05M-$4.63M$24.63$88.62-$239.48M2024-04-23
2021-12-31$673.59K$21.79M$647.82K$13.68M$54.73$98.60-$186.48M2024-04-23
2022-12-311.Christopher Gibson$6.32M-$5.83M$2.05M-$4.63M$24.63$88.62-$239.48M2023-04-28
2021-12-31$673.59K$21.79M$647.82K$13.68M$54.73$98.60-$186.48M2023-04-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Vericel Corp (VCEL)United States$2.011B93.97
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Greenland Mines Ltd (GRML)United States$2.362B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Immunocore Holdings plc (IMCR)$1.613B-90.43
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51